A bold approach to improving outcomes

At Urovant, we live our core values every day, working together to create meaningful change. We bring passion, purpose, and care to our efforts in urology, and these qualities continue to drive us forward. We are excited to explore new possibilities for the future.

Image
Photograph of three Black women of different ages walking on the beach with arms around each other and laughing
Image
Photograph of three Black women of different ages walking on the beach with arms around each other and laughing
Image
Photograph of three Black women of different ages walking on the beach with arms around each other and laughing

Our product pipeline

Program
Phase 1
Phase 2
Phase 3
Filed
U.S. approval
Show Hide
Vibegron in men with OAB and BPH

Vibegron is being investigated in COURAGE, a phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of vibegron in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH).

 
Show Hide
URO-902

URO-902 is being investigated in a phase 2a, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy, safety, and tolerability of a single physician-administered dose of a novel gene therapy for patients with overactive bladder (OAB) who have not been adequately managed with oral or transdermal pharmacologic therapy for OAB.

 
Program
Show Hide
Vibegron in men with OAB and BPH

Vibegron is being investigated in COURAGE, a phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of vibegron in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH).

Phase 1
Phase 2
Phase 3
Filed
U.S. approval
 
Show Hide
URO-902

URO-902 is being investigated in a phase 2a, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy, safety, and tolerability of a single physician-administered dose of a novel gene therapy for patients with overactive bladder (OAB) who have not been adequately managed with oral or transdermal pharmacologic therapy for OAB.

Phase 1
Phase 2
Phase 3
Filed
U.S. approval
 

Visit Clinicaltrials.gov to learn more about clinical trials in urology.

Learn more
Image
Photograph of a young woman with curly silver hair and dark-rimmed glasses, slightly smiling
Image
Photograph of a young woman with curly silver hair and dark-rimmed glasses, slightly smiling
Image
Photograph of a young woman with curly silver hair and dark-rimmed glasses, slightly smiling
PARTNERS

Building for a brighter future

Urovant is seeking licensing opportunities as well as new innovations that can accelerate our mission to improve the quality of care for patients, their families, and care partners.

Image
Shoulders-down photo of clinician wearing stethoscope and holding computer tablet
Image
Shoulders-down photo of clinician wearing stethoscope and holding computer tablet
Image
Shoulders-down photo of clinician wearing stethoscope and holding computer tablet

Urovant Medical Affairs

Urovant Sciences Medical Affairs supports our ongoing product development efforts, providing scientific support to healthcare professionals, including opportunities for investigator-initiated trials and medical education grants.